Leucine

Leucine

SCHEMBL5874172

CC(C)C[C@H](N)C(=O)O.c1cc[nH]c1

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.72
SLC1A3 P43003 7/20 0.57
SLC1A2 P43004 7/20 0.57
SLC1A1 P43005 7/20 0.48
RNPEP Q9H4A4 2/20 0.44
ANPEP P15144 1/20 0.44
DNPEP Q9ULA0 1/20 0.44
GRIK1 P39086 4/20 0.43
GRIA2 P42262 2/20 0.43
GRIA4 P48058 2/20 0.43
GRIK3 Q13003 2/20 0.43
GRIK5 Q16478 2/20 0.43
GRIK2 Q13002 2/20 0.43
GRIA1 P42261 1/20 0.43
LARS1 Q9P2J5 1/20 0.41
GRM2 Q14416 1/20 0.41
GRM3 Q14832 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leucine SCHEMBL28356659 1.00 SLC7A5 (0.72) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
D-Leucine SCHEMBL9449950 0.85 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
Leucine SCHEMBL8568060 0.85 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
D-Leucine SCHEMBL9100148 0.85 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
Leucine SCHEMBL8568063 0.85 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
Leucine SCHEMBL25241602 0.85 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
D-Leucine SCHEMBL42012 0.85
Leucine SCHEMBL331557 0.85 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
Leucine SCHEMBL20362356 0.85
Leucine SCHEMBL3888 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7090993-B2 Method of assaying pyrrole-containing biological compounds ROWETT RESEARCH INSTITUTE (GB) 2006-08-15 US disclosed
US-7067267-B2 Method of assaying pyrrole-containing biological compounds ROWETT RESEARCH INSTITUTE (GB) 2006-06-27 US disclosed
US-20040072370-A1 Method of assaying pyrrole-containing biological compounds ROWETT RESEARCH INSTITUTE (GB) 2004-04-15 US disclosed
US-20040063222-A1 Method of assaying pyrrole-containing biological compounds ROWETT RESEARCH INSTITUTE (GB) 2004-04-01 US disclosed
US-6667180-B2 Detecting preferential particles in sample; obtain sample, incubate with label, determine amount of bound particles ROWETT RESEARCH INSTITUTE (GB) 2003-12-23 US disclosed
EP-1325339-A2 METHOD OF ASSAYING PYRROLE-CONTAINING BIOLOGICAL COMPOUNDS The Rowett Research Institute (GB) 2003-07-09 EP disclosed
US-20020048779-A1 Method of assaying pyrrole-containing biological compounds ROWETT RESEARCH INSTITUTE (GB) 2002-04-25 US disclosed
WO-2002029409-A2 METHOD OF ASSAYING PYRROLE-CONTAINING BIOLOGICAL COMPOUNDS ROWETT RESEARCH INSTITUTE (GB) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072370-A1 Method of assaying pyrrole-containing biological compounds SHBG, HLA-B, LY96 SLC7A5 4535/4885SLC1A3 4680/4885SLC1A2 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.